Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selegiline Transdermal System (STS) for HIV-Associated Cognitive Impairment
NCT00013585Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selegiline in HIV-associated cognitive impairment, sponsored by National Institute of Allergy and Infectious Diseases. Status: completed.
02
Drugs
selegiline
03
Conditions
HIV-associated cognitive impairment
Beyond the preview
Go deeper on NCT00013585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00013585.